Pancreatic cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Pancreatic cancer}} | {{Pancreatic cancer}} | ||
NEW TREATMENTS | |||
Irinotecan in an encapsulated form inside a nanoliposome is being used in advanced pancreatic cancer patients who have been earlier been treated using gemcitabine-based chemotherapy. <ref name="pmid27140876">{{cite journal |vauthors=Chiang NJ, Chang JY, Shan YS, Chen LT |title=Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer |journal=Expert Opin Pharmacother |volume=17 |issue=10 |pages=1413–20 |year=2016 |pmid=27140876 |doi=10.1080/14656566.2016.1183646 |url=}}</ref> | |||
Liposomal Irinotecan is used along with leucovorin and fluorouracil.<ref name="pmid26615328">{{cite journal |vauthors=Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT |title=Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial |journal=Lancet |volume=387 |issue=10018 |pages=545–57 |year=2016 |pmid=26615328 |doi=10.1016/S0140-6736(15)00986-1 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 17:38, 13 November 2017
|
Pancreatic cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic cancer future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Pancreatic cancer future or investigational therapies |
|
FDA on Pancreatic cancer future or investigational therapies |
|
CDC on Pancreatic cancer future or investigational therapies |
|
Pancreatic cancer future or investigational therapies in the news |
|
Blogs on Pancreatic cancer future or investigational therapies |
|
Risk calculators and risk factors for Pancreatic cancer future or investigational therapies |
NEW TREATMENTS
Irinotecan in an encapsulated form inside a nanoliposome is being used in advanced pancreatic cancer patients who have been earlier been treated using gemcitabine-based chemotherapy. [1]
Liposomal Irinotecan is used along with leucovorin and fluorouracil.[2]
References
- ↑ Chiang NJ, Chang JY, Shan YS, Chen LT (2016). "Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer". Expert Opin Pharmacother. 17 (10): 1413–20. doi:10.1080/14656566.2016.1183646. PMID 27140876.
- ↑ Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT (2016). "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial". Lancet. 387 (10018): 545–57. doi:10.1016/S0140-6736(15)00986-1. PMID 26615328.